Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

Trial Profile

Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Insulin lispro (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms SORELLA 2
  • Sponsors Sanofi
  • Most Recent Events

    • 11 Dec 2017 The U.S. Food and Drug Administration has approved Admelog (insulin lispro injection), indicated to improve control in blood sugar levels in adults and pediatric patients aged 3 years and older with type 1 diabetes mellitus and adults with type 2 diabetes mellitus, as reported in a US FDA media release.
    • 13 Jun 2017 Results of SORELLA 1 and SORELLA 2 trials presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top